|Bid||93.50 x 900|
|Ask||0.00 x 900|
|Day's Range||93.43 - 96.11|
|52 Week Range||69.38 - 125.86|
|PE Ratio (TTM)||23.51|
|Earnings Date||Jul 26, 2018 - Jul 30, 2018|
|Forward Dividend & Yield||3.84 (3.86%)|
|1y Target Est||113.62|
Yahoo Finance's Alexis Christoforous and Jared Blikre break down the latest market action after the Trump administration released details on the latest round of China tariffs, to which China has responded in kind. In other news, the June Empire State Manufacturing Survey beat Wall Street expectations on nearly every front.
This analysis is intended to introduce important early concepts to people who are starting to invest and want to begin learning the link between AbbVie Inc (NYSE:ABBV)’s fundamentals and stockRead More...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 20) Agios Pharmaceuticals Inc (NASDAQ: AGIO )(announced initiation ...
North Chicago, Illinois-based AbbVie Inc.'s stock finished Wednesday's session 0.24% higher at $98.25 with a total trading volume of 4.68 million shares. The Company's shares have advanced 37.95% over the past year.
The Civic 50 recognizes AbbVie as one of the most community-minded companies in the U.S. - For the fifth consecutive year, AbbVie teams up with leading nonprofits to enhance education and opportunities for the underserved. - The AbbVie Foundation has impacted nearly 19 million lives around the world since it was established in 2014.
LONDON, UK / ACCESSWIRE / June 19, 2018 / If you want access to our free research report on AbbVie Inc. (NYSE: ABBV), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ABBV as the Company’s latest news hit the wire. On June 15, 2018, the Company announced that it has presented investigational data from a new analysis of undetectable minimal residual disease (uMRD) rates from the pivotal Phase-3 MURANO trial, assessing venetoclax in combination with rituximab (VenR) in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) during the 23rd European Hematology Association (EHA) Annual Congress, Stockholm, held on June 16, 2018.
Bristol-Myers (BMY) announces positive results on oncology drug Empliciti. The company's blockbuster drug, Opdivo, was also approved in China for lung cancer.
The new tax bill cuts the overall corporate tax rate to 21 percent, and allows income from overseas to be taxed at about half that rate – to as low as 10 percent. AbbVie Inc. (ABBV.N) is a case in point. Its Chief Executive Richard Gonzalez told investors earlier this year that because of the change to a territorial system, whereby only profits reported by domestic subsidiaries face U.S. tax, the U.S. drugmaker expects its tax rate to fall to 9 percent this year from around 22 percent in recent years.
NEW YORK, NY / ACCESSWIRE / June 18, 2018 / U.S. market plunged on Friday, but well-off session lows as investors appeared to look at previous signs of escalating trade tension between Washington and Beijing. ...
The new tax bill cuts the overall corporate tax rate to 21 percent, and allows income from overseas to be taxed at about half that rate – to as low as 10 percent. AbbVie Inc. is a case in point. Its Chief Executive Richard Gonzalez told investors earlier this year that because of the change to a territorial system, whereby only profits reported by domestic subsidiaries face U.S. tax, the U.S. drugmaker expects its tax rate to fall to 9 percent this year from around 22 percent in recent years.
Several big pharma companies are about to lose patent exclusivity for blockbuster drugs. Should investors be worried?
Eli Lilly (LLY)/AstraZeneca (AZN) discontinue two late-stage studies on Alzheimer's disease candidate, lanabecestat. Merck's Keytruda gets FDA nod for two new indications.
NEW YORK, June 15, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Canopy ...
- 83 percent (n=100) of 121 patients who achieved undetectable minimal residual disease (uMRD) at the end of combination therapy with VenR (n=194), maintained uMRD and were progression-free at 13.8 months ...
NORTH CHICAGO, Ill. , June 14, 2018 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) declared a quarterly cash dividend of $0.96 per share. The cash dividend is payable Aug. 15, 2018 ...
- Upadacitinib showed improvements in physical function, a measure that assesses patients' ability to perform daily activities and level of disability(1,2,3) - A reduction in joint pain was reported by ...
AbbVie (ABBV) and Roche's (RHHBY) cancer drugs, Venclexta and Rituxan receive approval for combination use in second-line chronic lymphocytic leukemia.
Given the growing interest in JAK-inhibitor based treatments, here's a look at some companies that are looking to change the ways to treat autoimmune diseases.